Doctormag
  • Home
  • Categories
    • Aesthetics Surgery
    • Antonio Giordano
    • Dentist
    • Dermatology and Aesthetics
    • General Medicine
    • Healthcare Professions
    • Hygiene And Safety
    • Pharmaceutic Sector
    • Specialized Medicine
    • Unconventional Medicine
    • Wellness and Dieting
    • Works and Research
  • Pages
    • Handbook
    • Institutional Links
    • Medical Blogs
    • Privacy
    • Project
  • Rubrics
  • News
  • Video
  • Events
  • Join
Home » General Medicine » THE EFFICACY OF TELMISARTAN IN THE METABOLIC SYNDROME

THE EFFICACY OF TELMISARTAN IN THE METABOLIC SYNDROME

Jun 16, 2010 by admin

the-efficacy-of-telmisartan-in-the-metabolic-syndrome

The Metabolic Syndrome is a clinical condition characterized by the presence of multiple cardiovascular risk factors in the same subject, and particularly, hypertension and insulin resistance.

Telmisartan is an antihypertensive agent with partial activity on peroxisome proliferator-activated gamma receptor (PPAR-y) and is able to improve insulin sensitivity and lipid profile in patients with Metabolic Syndrome. A study of the metabolic effect of telmisartan and losartan in patients with hypertension associated with Metabolic Syndrome has been carried out.

In this randomized and double blind study, patients with Metabolic Syndrome were treated with a daily dose of telmisartan (80 mg) or Losartan (50 mg) for a period of 3 months.

Patients were treated in groups of twenty: at the beginning and at the end of their treatment, fasting and post-prandial plasma glucose, sensitivity to insulin, glycosylated hemoglobin, and median systolic and diastolic blood pressure over 24 hours were measured.

Unlike losartan, telmisartan has been shown capable of significantly reducing (p less than 0.05), plasma glucose values, insulin resistance as well as glycosylated hemoglobin; results on lowering blood pressure were also superior with telmisartan.

In conclusion, this study has confirmed and corroborated the capacity of telmisartan to not only control the average blood pressure over 24 hours, but also to be capable of insulin-sensitizer activity, which can be explained by its partial activity on PPAR-y.

REFERENCES:

Cardiovascular Diabetology May 2005, 4:6

Metabolic effect of telmisartan and losartan in hypertensive patients with Metabolic Syndrome

Vitale, Mercury, Castiglioni, Cornoldi Tullio, Fini Volterrani and Rosano



Luca Gabriele Punziano
General Practitioner Specializing in Preventive Medicine and Hygiene, Umberto I Hospital, Rome, Italy

Related Posts

  • Metabolic syndrome and insulin – resistance: one, none, hundred, or thousand risk factors? Metabolic syndrome and insulin – resistance: one, none, hundred, or thousand risk factors?

    Posted on Sep 1, 2011

  • Snoring Snoring

    Posted on Jun 8, 2011

  • Sartans Sartans

    Posted on Dec 22, 2010

  • Obesity Emergency

    Posted on Jan 15, 2010

Tags

  • antihypertensive
  • clinical condition
  • glycosylated
  • hypertension
  • insulin resistance
  • Losartan
  • metabolic syndrome
  • multiple cardiovascular risk
  • peroxisome proliferator-activated gamma receptor
  • PPAR-y
  • Telmisartan
  • TELMISARTAN IN

Share This

Facebook

Events

There are no events to display

February 2019
M T W T F S S
« Oct    
 123
45678910
11121314151617
18192021222324
25262728  

Tags

3d adipose tissue AIDS Alessandro Franco animation body cancer carcinoma Carmine Martino cellulite chemotherapy diabetes diet disease Doctor Doctormag emergency Epidermis health heart Heart Rate Variability HIV Human Health Foundation Onlus hyperglycemia hypertension liposuction liquid nitrogen medical medical video medicine muscles nutrition Obesity osteoporosis Pier Antonio Bacci pregnancy prof Antonio Giordano research Sbarro Health Research Organization skin surgery therapy turitv tv women

NETWORK

  • Ble Group

PARTNERS

  • Gruppo Mag
  • Sbarro Health Foundation
  • SCR Italy